No supplier or customer ties in MDWD's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
No earnings record for MDWD on the current feed.
Nothing on the wire mentions MDWD yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How MDWD has moved on past release days vs its typical ±2.4% day, and how often it closed up. Computed from daily closes — not a forecast.